Evidence map›Paper›PMID 31172720›Full record

ArticleAllergy, asthma & immunology research2019

Add-on Tiotropium in Chinese Patients With Moderate Asthma: A Pooled Subgroup Analysis of MezzoTinA-Asthma 1 and 2.

Jiangtao Lin, Huanying Wan, Jian Kang, Qianli Ma, Ping Chen, Meiling Jin, Haoyan Wang, Shuang Liu, Qinglin Hao, Yong Lin and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, asthma & immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 1 country.

Jiangtao LinDepartment of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China. jiangtao_l@263.net.ORCID https://orcid.org/0000-0001-6432-0837
Huanying WanDepartment of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-1729-0062
Jian KangDepartment of Pulmonary Diseases, the First Hospital of China Medical University, Shenyang, China.ORCID https://orcid.org/0000-0001-6509-048X
Qianli MaDepartment of Pulmonary Diseases, Xinqiao Hospital, Chongqing, China.ORCID https://orcid.org/0000-0003-4504-1933
Ping ChenDepartment of Pulmonary Diseases, the Second Xiangya Hospital of Central South University, Changsha, China.ORCID https://orcid.org/0000-0002-9901-8395
Meiling JinDepartment of Pulmonary Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-8663-0702
Haoyan WangDepartment of Pulmonary Diseases, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, China.ORCID https://orcid.org/0000-0001-7688-5915
Shuang LiuDepartment of Pulmonary and Critical Care Medicine, Capital Medical University Affiliated Anzhen Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-0658-5738
Qinglin HaoDepartment of Pulmonary Diseases, First Affiliated Hospital of Kunming Medical University, Kunming, China.ORCID https://orcid.org/0000-0002-6706-6368
Yong LinDepartment of Pulmonary Diseases, Nanjing Chest Hospital, Nanjing, China.ORCID https://orcid.org/0000-0002-1018-3272
Lin SuBoehringer Ingelheim, Shanghai, China.ORCID https://orcid.org/0000-0002-8111-5541
Na HuBoehringer Ingelheim, Shanghai, China.ORCID https://orcid.org/0000-0003-0153-8569
Boehringer Ingelheim (China) · CNBeijing Anzhen Hospital · CNBeijing Friendship Hospital · CNCentral South University · CNChina-Japan Friendship Hospital · CNFirst Hospital of China Medical University · CNFudan University · CNKunming Medical University · CNNanjing Chest Hospital · CNRuijin Hospital · CNXinqiao Hospital · CN

Funding

Boehringer Ingelheim
6 · The paper itself

Abstract

purposeAsthma affects approximately 30 million patients in China; however, tiotropium data for Chinese patients is limited. This study aimed to assess the efficacy and safety of tiotropium in Chinese patients with moderate symptomatic asthma.

methodsA

resultsFor both FEV1 peak

conclusionsOnce-daily tiotropium, as add-on to medium-dose ICS, was effective and well tolerated for Chinese patients with moderate symptomatic asthma, consistent with the main analysis.

Indexed as

AdultasthmaChineseefficacytiotropium

Identifiers

PMID31172720
PMCPMC6557774
OpenAlexW2950689810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.